ClinicalTrials.gg
TerminatedNCT05226507Updated Aug 6, 2026

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

A Phase 1 interventional study of NXP800 in Advanced Solid Tumor, Ovarian Cancer and Ovarian Clear Cell Carcinoma, sponsored by Nuvectis Pharma, Inc.. Terminated at 22 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Nuvectis Pharma, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Study terminated due to various reasons impacting the feasibility of future clinical development

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 275 open to participants now, 452 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Enrollment
759th of 1,499
45 · median 47
Started
2021
with 95 others
Phase 1
548 of 1,780
73 open now
Registered
1,433rd of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 759th largest by enrollment of the 1,499 interventional ones that give a count, is one of 96 that started in 2021, is one of 548 in phase 1, and was the 1,433rd registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

275 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.

Read the detailed description

Part A of the study is a dose escalation by cohort study of NXP800 administered to patients with advanced cancers. The study will identify the maximum tolerated dose (MTD) and propose dose and dose schedules for future studies.

In Part B doses selected in Part A are administered to patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

03

Conditions studied

  • Advanced Solid Tumor
  • Ovarian Cancer
  • Ovarian Clear Cell Carcinoma
  • Ovarian Clear Cell Tumor
  • Ovarian Clear Cell Adenocarcinoma
  • Ovarian Endometrioid Adenocarcinoma
  • Ovarian Endometrioid Tumor
  • ARID1A Gene Mutation

Keywords

  • Solid Tumor
  • Carcinoma
  • Neoplasms
  • Adenocarcinoma
  • ARID1a
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Part A Inclusion Criteria:

  • Provide written .
  • 18 years old or older.
  • of at least 12 weeks.
  • - or cytologically-confirmed, advanced, , and/or progressive solid tumors for whom there is no authorized or effective therapy available, or for whom such therapies are considered inappropriate by the Investigator (in Part B, subjects with specific cancer types will be enrolled; Specific criteria will be introduced in a protocol amendment).
  • according to (RECIST) Version 1.1.
  • (ECOG) performance status of ≤ 2.

Part A Exclusion Criteria:

  • Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, or agent within 28 days, (42 days for nitrosoureas, mitomycin-C) of first dose of NXP800. Subjects can continue to receive bisphosphonates due to metastatic bone disease or GnRH agonists if they have prostate cancer.
  • Ongoing toxic manifestations of previous treatments > Grade 2.
  • Subjects with treated are eligible if there is no evidence of progression for at least 28 days after central nervous system (CNS) directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the Screening period.
  • Female subjects who can become pregnant (or are already pregnant or lactating).
  • Male subjects with partners of (unless they agree to take measures not to father children by using a barrier method of (condom plus spermicide) or to sexual abstinence).

Part B Inclusion Criteria:

  • Provide written informed consent.
  • 18 years old or older.
  • Subjects with the following ARID1a mutated, ovarian/fallopian tube/primary peritoneal cancer histologies (ARID1a mutation status determined by a DNA-based Next Generation Sequencing test):

    • Clear cell ovarian carcinoma (≥ 50% clear cell carcinoma with no serous differentiation)
    • Endometrioid ovarian carcinoma
  • Subjects must have disease progression within 6 months (182 days) from completion of platinum-based therapy (6 months should be calculated from the date of the last administered dose of platinum therapy to the date of radiographic imaging showing progression)
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
  • Subjects with a BRCA mutation must have received prior treatment with a PARP inhibitor.
  • Subjects must have received at least 1 but not more than 3 prior systemic lines of anticancer therapy, including at least 1 containing bevacizumab.

    • Adjuvant + are considered one line of therapy
    • Maintenance therapy (i.e., bevacizumab, PARP inhibitors) will be considered as part of the preceeding line of therapy and are not counted independently.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Subjects must have a sufficient archival Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimen, or be willing to consent to a fresh tissue during the study.

Part B Exclusion Criteria:

  • Subjects with disease that did not respond to, or has progressed during or within 4 weeks of the last dose of first-line platinum containing chemotherapy.
  • Radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, or investigational agent within 28 days, (42 days for nitrosoureas, mitomycin-C) of first dose of NXP800.
  • Ongoing toxic manifestations of previous treatments > Grade 2, with the exception of alopecia.
  • Subjects with treated brain metastases are eligible if there is no evidence of progression for at least 12 weeks while off after central nervous system (CNS) directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the Screening period.
  • Female subjects who can become pregnant (or are already pregnant or lactating).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Part A: Dose Escalation

    Escalating doses of NXP800 administered orally once or twice daily.

    Drug: NXP800

  • Experimental
    Part B: Expansion in Ovarian Cancers Cohort 1

    Subjects will be treated with NXP800 at 50 mg/day orally.

    Drug: NXP800

  • Experimental
    Part B: Expansion in Ovarian Cancers Cohort 2

    Subjects will be treated with NXP800 at 75 mg/day orally.

    Drug: NXP800

Interventions

  • DrugNXP800

    NXP800 is an anti-neoplastic, oral small molecule.

06

What researchers measure

Primary outcomes

  1. Part A: Number of patients with treatment related adverse events, clinical laboratory abnormalities, dose limiting toxicities

    Time frame: Day 28

  2. Part B: Estimates of disease response by RECIST v 1.1

    Time frame: Baseline to 30 days post last dose of NXP800

  3. Part B: Number of patients with treatment related adverse events, and/or clinical laboratory abnormalities.

    Time frame: Baseline to 30 days post last dose of NXP800

Secondary outcomes

  1. Area under the concentration-time curve (AUC) of NXP800

    Time frame: First dose through Day 29

  2. Maximum observed concentration (Cmax) of NXP800

    Time frame: First dose through Day 29

  3. Time to peak concentration (Tmax) of NXP800

    Time frame: First dose through Day 29

  4. Half-life (T1/2) of NXP800

    Time frame: First dose through Day 29

07

Study locations

22 sites
  • Honor Health
    Phoenix, Arizona 85016, United States
  • UC San Diego Health - Moores Cancer Center
    La Jolla, California 92093, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Yale Gynecologic Oncology
    New Haven, Connecticut 06511, United States
  • Florida Cancer Specialists South
    Fort Myers, Florida 33901, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • Florida Cancer Specialists Research North
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists Research East
    West Palm Beach, Florida 33401, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • Women's Cancer Care Associates
    Albany, New York 12208, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • OU Health Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Oklahoma Cancer Specialists and Research Institute
    Tulsa, Oklahoma 74146, United States
  • Oncology Associates of Oregon
    Eugene, Oregon 97401, United States
  • Sidney Kimmel Cancer Center, Asplundh Cancer Pavilion
    Willow Grove, Pennsylvania 19090, United States
  • Texas Oncology
    Fort Worth, Texas 76104, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Royal Marsden Hospital
    Sutton, Sutton Surrey SM2 5PT, United Kingdom
  • Addenbrookes Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • The Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jan 2025, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2022
First posted
Feb 7, 2022
StartActual
Dec 31, 2021
Primary completionActual
Jan 1, 2025
CompletionActual
Jan 1, 2025
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05226507
Lead sponsor
Nuvectis Pharma, Inc.
Collaborators
Gynecologic Oncology Group Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Responsible party
Sponsor
First posted
Feb 7, 2022
Start date
Dec 31, 2021
Primary completion
Jan 1, 2025
Completion
Jan 1, 2025
Last update
Aug 6, 2026

Study contacts

Udai Banerji, Prof
principal investigator · Institute of Cancer Research, Royal Marsden Foundation Trust
Susana Banerjee, Dr
principal investigator · Institute of Cancer Research, Royal Marsden NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion